ProCE Banner Activity

First-in-Human Study of GC012F: BCMA/CD19 Dual-Targeted CAR T-Cell Therapy for Relapsed/Refractory Myeloma

Slideset Download
Conference Coverage
Updated results from this investigator-initiated study suggest that GC012F confers rapid, deep, durable responses among high-risk and heavily pretreated patients with relapsed/refractory multiple myeloma.

Released: June 09, 2022

Expiration: June 08, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab